Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aradigm Corporation    ARDM

ARADIGM CORPORATION (ARDM)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
2.26(c) 2.06(c) 2.03(c) 2.12(c) 2.29(c) Last
2 664 898 1 024 175 323 338 628 446 1 004 776 Volume
-8.85% -1.46% +4.43% +8.02% Change
More quotes
Financials ($)
Sales 2017 12,1 M
EBIT 2017 -8,22 M
Net income 2017 -11,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 9,14 M
EBIT 2018 -8,71 M
Net income 2018 -11,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 2,65x
Capi. / Sales2018 3,51x
Capitalization 32,1 M
More Financials
Company
Aradigm Corp. is a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists.Its technologies include diabetes and pain management, AERx essence devices.The... 
More about the company
Latest news on ARADIGM CORPORATION
08:38p THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
01:21a ARADIGM CORPORATION : Pomerantz Law Firm Reminds Shareholders with Losses on the..
01/18 ARADIGM LOSS NOTICE : Rosen Law Firm Reminds Aradigm Corporation Investors of Im..
01/18 ARADIGM : The Klein Law Firm Notifies Investors of an Investigation Concerning P..
01/18 ARDM Law Offices of Howard G. Smith Commences Investigation on Behalf of Arad..
01/17 ARADIGM CORPORATION : Pawar Law Group Announces a Securities Class Action Lawsui..
01/17 ARDM The Law Offices of Vincent Wong Reminds Investors of an Investigation In..
01/17 ARADIGM : FDA Advisory Committee Not Convinced of Linhaliqs Benefits in Bronchie..
01/16 ARDM The Law Offices of Vincent Wong Notifies Investors of an Investigation I..
01/15 Holzer & Holzer Announces Class Action Lawsuit Filed on Behalf of Investors i..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
10:50pARADIGM ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Los.. 
01/17Aradigm Corporation : Pawar Law Group Announces a Securities Class Action Law.. 
01/1742 Biggest Movers From Yesterday  
01/17SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors.. 
01/16Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those .. 
More tweets
Qtime:90
News from SeekingAlpha
03:44p Key events next week - healthcare
01/17 ARADIGM, THE FINAL COUNTDOWN - OR : Was The 'Negative' Vote A Red Herring?
01/15 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's MS Win, Aradigm FDA Panel Woes, A..
01/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 13, 2018
01/12 Midday Gainers / Losers (1/12/2018)
Chart ARADIGM CORPORATION
Duration : Period :
Aradigm Corporation Technical Analysis Chart | ARDM | US0385054004 | 4-Traders
Technical analysis trends ARADIGM CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 10,0 $
Spread / Average Target 372%
EPS Revisions
Managers
NameTitle
Igor Gonda President, Chief Executive Officer & Director
John M. Siebert Chairman
Nancy E. Pecota Chief Financial Officer
Juergen Kurt Froehlich Chief Medical Officer
David Ian Bell Director
Sector and Competitors
1st jan.Capitalization (M$)
ARADIGM CORPORATION-69.70%32
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-0.50%39 890
VERTEX PHARMACEUTICALS4.76%39 754
GENMAB10.50%11 455
BLUEBIRD BIO INC2.25%8 346